Citations

Clear

1434 citation(s) found for "Uk, Nathan".

High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment
Dogra, Prerna , Šambula, Lana, Saini, Jasmine , Thangamuthu, Karthik, Athimulam, Shobana , Delivanis, Danae A. , Baikousi, Dimitra, Nathani, Rohit , Zhang, Catherine D , Genere, Natalia , Salman, Zara, Ambroziak, Urszula , Garcia, Raul Gregg , Achenbach, Sara J., Atkinson, Elizabeth J. , Singh, Sumitabh , Kaštelan, Darko , Garcia, Raul G, Bancos, Irina , Saini, Jasmine , Ambroziak, Urszula , Garcia, Raul G , Kastelan, Darko , Thangamuthu, Karthik, Turcu, Adina F. , LeBrasseur, Nathan K. , Bancos, Irina

Mayo Clinic

European Journal of Endocrinology | August 16, 2023 | Volume: 189 | Issue: 3 | Pages: 318-326

10.1093/ejendo/lvad113 | PMID 37590964 Get It

Abstract Objective Frailty, characterized by multi-system decline, increases vulnerability to adverse health outcomes and can be measured using Frailty Index (FI). We aimed to assess the prevalence of frailty in patients with adrenal disorders (based on hormonal sub-type) and examine association between FI and performance-based measures of physical function. Design Multi-centre, cross-sectional study (March 2019-August 2022). Methods Adult patients with adrenal disorders (non-functioning adrenal adenomas [NFA], mild autonomous cortisol secretion [MACS], Cushing syndrome [CS], primary aldosteronism [PA]) and referent subjects without adrenal disorders completed a questionnaire encompassing 47 health variables (comorbidities, symptoms, daily living activities). FI was calculated as the average score of all variables and frailty defined as FI ≥ 0.25. Physical function was assessed with hand grip, timed up-and-go test, chair rising test, 6-minute walk test, and gait speed. Results Compared to referent subjects (n = 89), patients with adrenal disorders (n = 520) showed increased age, sex, and body mass index-adjusted prevalence of frailty (CS [odds ratio—OR 19.2, 95% confidence interval—CI 6.7-70], MACS [OR 12.5, 95% CI 4.8-42.9], PA [OR 8.4, 95% CI 2.9-30.4], NFA [OR 4.5, 95% CI 1.7-15.9]). Prevalence of frailty was similar to referent subjects when post-dexamethasone cortisol was <28 nmol/L and was higher when post-dexamethasone cortisol was 28-50 nmol/L (OR 4.6, 95% CI 1.7-16.5). FI correlated with all measures of physical function (P < .001). Conclusions Whilst frailty prevalence was highest in patients with adrenocortical hormone excess, even patients with NFA demonstrated an increased prevalence compared to the referent population. Future longitudinal studies are needed to evaluate the impact of various management strategies on frailty.
Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report
Núñez, Nicolás A. , Kung, Simon , Voort, Jennifer L. Vande , Schak, Kathryn M. , Boehm, Stacey M., Carpenter, Brooke, Johnson, Emily K. , Malyshev, Grigoriy, Smits, Nathan , Adewunmi, Daniel O., Brown, Sarah K , Singh, Balwinder , Joseph, Boney , Vande Voort, Jennifer L , Singh, Balwinder , Joseph, Boney , Pazdernik, Vanessa , Smits, Nathan

Mayo Clinic

Pharmaceuticals | August 16, 2023 | Volume: 16 | Issue: 8 | Pages: 1164

10.3390/ph16081164 | PMID 37631079 Get It

Intravenous (IV) ketamine and FDA-approved intranasal (IN) esketamine are increasingly used for treatment-resistant depression (TRD). Preliminary studies have suggested a synergistic effect of ketamine and lamotrigine, although the data are inconclusive. Herein, we report the response to serial ketamine/esketamine treatment among patients with TRD with or without lamotrigine therapy. In this historical cohort study, we included adult patients with TRD who received serial IV racemic ketamine (0.5 mg/kg over 40−100 min) or IN esketamine (56/84 mg) treatments. A change in depressive symptoms was assessed using the 16-item Quick Inventory of Depressive Symptomatology self-report (QIDS-SR) scale. There were no significant differences in response or remission rates among the patients on or not on lamotrigine during the ketamine/esketamine treatments. For a percent change in the QIDS-SR from baseline, no interaction was found between the lamotrigine groups and treatment number (p = 0.70), nor the overall effect of the group (p = 0.38). There was a trend towards lower dissociation (based on the CADSS score) among current lamotrigine users, especially in patients who received IV ketamine. A major limitation is the limited number of patients taking lamotrigine (n = 13). This preliminary study provides insufficient evidence that continuing lamotrigine therapy attenuates the antidepressant effect of repeated ketamine/esketamine; however, there seems to be a signal toward attenuating dissociation with lamotrigine in patients receiving serial ketamine treatments. Further observational studies or randomized controlled trials are needed to replicate these findings.
Imaging of Fontan-Associated Liver Disease
Brown, Mark J. F. , Kolbe, Amy B. , Hull, Nathan C. , Hilscher, Moira , Kamath, Patrick S. , Yalon, Mariana , Gu, Chris N., Amawi, Ali Dean Tahboub , Wells, Michael , Brown, Mark J., Venkatesh, Sudhakar K.

Mayo Clinic

Journal of Computer Assisted Tomography | August 14, 2023 | Volume: 48 | Issue: 1 | Pages: 1-11

10.1097/rct.0000000000001533 | PMID 37574655 Get It

Abstract The Fontan procedure is the definitive treatment for patients with single-ventricle physiology. Surgical advances have led to a growing number of patients surviving into adulthood. Fontan-associated liver disease (FALD) encompasses a spectrum of pathologic liver changes that occur secondary to altered physiology including congestion, fibrosis, and the development of liver masses. Assessment of FALD is difficult and relies on using imaging alongside of clinical, laboratory, and pathology information. Ultrasound, computed tomography, and magnetic resonance imaging are capable of demonstrating physiologic and hepatic parenchymal abnormalities commonly seen in FALD. Several novel imaging techniques including magnetic resonance elastography are under study for use as biomarkers for FALD progression. Imaging has a central role in detection and characterization of liver masses as benign or malignant. Benign FNH-like masses are commonly encountered; however, these can display atypical features and be mistaken for hepatocellular carcinoma (HCC). Fontan patients are at elevated risk for HCC, which is a feared complication and has a poor prognosis in this population. While imaging screening for HCC is widely advocated, no consensus has been reached regarding an optimal surveillance regimen.
Changes in amount and intensity of physical activity over time in breast cancer survivors
Marell, Paulina S. , Herrmann, Joerg , Larson, Nicole L. , D’Andre, Stacy D, Barksdale, Toure, Loprinzi, Charles L. , Ruddy, Kathryn J. , D'Andre, Stacy D, Ehlers, Diane K. , Ruddy, Kathryn J , Vierkant, Robert A. , Olson, Janet E. , LeBrasseur, Nathan K. , Stan, Daniela , Cheville, Andrea , Barksdale, Touré, Couch, Fergus J.

Mayo Clinic

JNCI Cancer Spectrum | August 9, 2023 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/jncics/pkad056 | PMID 37561108 Get It

Abstract Background Physical activity is associated with decreased breast cancer recurrence and mortality, as well as fewer treatment-related symptoms. Nevertheless, most breast cancer survivors do not meet physical activity guidelines. The purpose of this manuscript is to characterize physical activity trends over time in breast cancer survivors. Methods Mayo Clinic Breast Disease Registry participants received surveys at baseline and at 1 and 4 years after diagnosis; breast cancer recurrence and/or metastatic disease were exclusion criteria. Participants were considered to be meeting guidelines if they self-reported at least 150 minutes of moderate-intensity (eg, fast walking) and/or strenuous (eg, jogging) physical activity per week. Statistical analyses include analysis of covariance methods, paired t tests, conditional logistic regression models, and McNemar tests of homogeneity. Results A total of 171 participants were included in the analysis. The amount of total physical activity decreased over time (P = .07). Mild-intensity physical activity (eg, easy walking) decreased most over time (P = .05). Among participants aged 18-49 years, mild-intensity (P = .05) and moderate-intensity (P = .02) physical activity decreased over time. Strenuous-intensity physical activity levels decreased over time among participants with a normal body mass index (P = .002) and with obesity (P = .01). Conclusions We found a trend-level decrease in total physical activity over time, driven mostly by a decrease in mild-intensity physical activity. Young breast cancer survivors are especially likely to reduce their physical activity over time. Further research on implementing physical activity guidelines in clinical practice is warranted.
Medically ready for discharge: A multisite “point‐in‐time” assessment of hospitalized patients
Bann, Maralyssa , Meo, Nicholas , Ou, Amy , Rosenthal, M , Khawaja, Hussain , Goodman, Leigh Anne , Barone, Melanie, Coleman, Bernice , High, Heidi , Overbeek, Lori, Shelbourn, Pam, VerMaas, Lisa, Baughman, Amy W. , Sekaran, Adith, Cyrus, Rachel , O'Dorisio, Nathan, Beatty, Lane, Loica‐Mersa, Silvia , Kubey, Alan , Jaffe, Rebecca, Vokoun, Chad, Koom‐Dadzie, Kwame , Graves, Kencee , Helgerson, Paul , Ou, Amy , Rosenthal, Molly , Khawaja, Hussain , Goodman, Leigh A , Baughman, Amy , Loica-Mersa, Silvia , Kubey, Alan A , Koom-Dadzie, Kwame , Graves, Kencee , Tuck, Matthew , Helgerson, Paul , Lopez, J. P.

Mayo Clinic

Journal of Hospital Medicine | August 9, 2023 | Volume: 18 | Issue: 9 | Pages: 795-802

10.1002/jhm.13184 | PMID 37553979 Get It

Abstract Background Time spent awaiting discharge after the acute need for hospitalization has resolved is an important potential contributor to hospital length of stay (LOS). Objective To measure the prevalence, impact, and context of patients who remain hospitalized for prolonged periods after completion of acute care needs. Design, Setting, and Participants We conducted a cross‐sectional “point‐in‐time” survey at each of 15 academic US hospitals using a structured data collection tool with on‐service acute care medicine attending physicians in fall 2022. Main Outcomes and Measures Primary outcomes were number and percentage of patients considered “medically ready for discharge” with emphasis on those who had experienced a “major barrier to discharge” (medically ready for discharge for ≥1 week). Estimated LOS attributable to major discharge barriers, contributory discharge needs, and associated hospital characteristics were measured. Results Of 1928 patients sampled, 35.0% ( n = 674) were medically ready for discharge including 9.8% ( n = 189) with major discharge barriers. Many patients with major discharge barriers (44.4%; 84/189) had spent a month or longer medically ready for discharge and commonly (84.1%; 159/189) required some form of skilled therapy or daily living support services for discharge. Higher proportions of patients experiencing major discharge barriers were found in public versus private, nonprofit hospitals (12.0% vs. 7.2%; p = .001) and county versus noncounty hospitals (14.5% vs. 8.8%; p = .002). Conclusions Patients experience major discharge barriers in many US hospitals and spend prolonged time awaiting discharge, often for support needs that may be outside of clinician control.
Energy use in moderate hypofractionation and stereotactic body radiotherapy for prostate cancer
Laughlin, Brady S. , Anderson, Justin D. , Hobbis, Dean , Armstrong, Michael , Vargas, Carlos , Yu, Nathan Y. , Laughlin, Brady S , Armstrong, Michael, Rong, Yi

Mayo Clinic

BJU International | August 9, 2023 | Volume: 132 | Issue: 6 | Pages: 648-650

10.1111/bju.16151 | PMID 37553875 Get It

Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Mullen, Nathan , Curneen, James , Donlon, Padraig, Gurnell, Mark , Dennedy, Michael Conall , Bancos, Irina , Gurnell, Mark , Dennedy, M Conall , Prakash, Punit , Bancos, Irina

Mayo Clinic

Endocrine Reviews | August 8, 2023 | Volume: 45 | Issue: 1 | Pages: 125-170

10.1210/endrev/bnad026 | PMID 37556722 Get It

Abstract Primary aldosteronism (PA) is the most common cause of secondary hypertension and is associated with increased morbidity and mortality when compared with blood pressure–matched cases of primary hypertension. Current limitations in patient care stem from delayed recognition of the condition, limited access to key diagnostic procedures, and lack of a definitive therapy option for nonsurgical candidates. However, several recent advances have the potential to address these barriers to optimal care. From a diagnostic perspective, machine-learning algorithms have shown promise in the prediction of PA subtypes, while the development of noninvasive alternatives to adrenal vein sampling (including molecular positron emission tomography imaging) has made accurate localization of functioning adrenal nodules possible. In parallel, more selective approaches to targeting the causative aldosterone-producing adrenal adenoma/nodule (APA/APN) have emerged with the advent of partial adrenalectomy or precision ablation. Additionally, the development of novel pharmacological agents may help to mitigate off-target effects of aldosterone and improve clinical efficacy and outcomes. Here, we consider how each of these innovations might change our approach to the patient with PA, to allow more tailored investigation and treatment plans, with corresponding improvement in clinical outcomes and resource utilization, for this highly prevalent disorder.
NCCN Guidelines® Insights: Survivorship, Version 1.2023
Sanft, Tara , Ansbaugh, Shannon, Ballinger, T.J., Demark‐Wahnefried, Wendy , Dickinson, Kristin , Fairman, Nathan, Felciano, Josephine, Flores, Tessa , Gabel, Nicolette , Goldman, Mindy, Henry, N. Lynn , Hill‐Kayser, Christine E. , Koura, Divya, Lee, Kimberly , McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Rodriguez, Maria Alma , Schapira, Lidia , Smith, Sophia K. , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Henry, N Lynn , Demark-Wahnefried, Wendy , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Friedman, Debra L. , Hudson, Melissa M. , Moore, Halle C. F. , O’Connor, Tracey L. , Overholser, Linda , Paskett, Electra D. , Pirl, William F. , Schwartz, Anna L. , Yang, Eric H.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 792-803

10.6004/jnccn.2023.0041 | PMID 37549906 Get It

The NCCN Guidelines for Survivorship are intended to help healthcare professionals address the complex and varied needs of cancer survivors. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for psychosocial and physical problems resulting from adult-onset cancer and its treatment; recommendations to help promote healthy behaviors and immunizations in survivors; and a framework for care coordination. These NCCN Guidelines Insights summarize recent guideline updates and panel discussions pertaining to sleep disorders, fatigue, and cognitive function in cancer survivors.
Chemoimmunotherapy in patients with extensive‐stage small cell lung cancer and a poor performance status
Agarwal, Muskan , Almquist, Daniel , Langlais, Blake, Leventakos, Konstantinos , Yu, Nathan Y. , Ernani, Vinicius , Langlais, Blake T., Yu, Nathan , Ernani, Vinicius , Liu, Alex C.H. , Manochakian, Rami

Mayo Clinic

Cancer | August 7, 2023 | Volume: 129 | Issue: 22 | Pages: 3546-3553

10.1002/cncr.34966 | PMID 37548029 Get It

Abstract Background Immune checkpoint inhibitor combined with platinum‐etoposide is the standard first‐line therapy for patients with extensive‐stage small cell lung cancer (ES‐SCLC). The phase 3 clinical trials that led to the approval of chemoimmunotherapy in ES‐SCLC excluded patients who had an Eastern Cooperative Group (ECOG) performance status (PS) of 2–3. Therefore, data on the efficacy of chemoimmunotherapy in patients with an ECOG PS of 2–3 are limited. Methods A retrospective analysis was performed on patients diagnosed with ES‐SCLC who received chemoimmunotherapy (atezolizumab or durvalumab) within the Mayo Clinic Health System between January 2016 and January 2021. The objective of this study was to compare the overall survival (OS), progression‐free survival (PFS), and best clinical response to therapy in patients with an ECOG PS of 0–1 vs. patients with an ECOG PS of 2–3 who received chemoimmunotherapy for newly diagnosed ES‐SCLC. Results In total, 82 patients were included in the study. The mean ± standard deviation age was 68.1 ± 8.3 years. Of these, 56 patients were identified with an ECOG PS of 0–1, and 26 patients were identified with an ECOG PS of 2–3. The median PFS was similar regardless of ECOG PS (5.8 months [95% CI, 4.3–6.0 months] in the ECOG PS 0–1 group vs. 4.1 months [95% CI, 3.8–6.9 months] in the ECOG PS 2–3; p = .2994). The median OS was also similar regardless of ECOG PS (10.6 months [95% CI, 8.4–13.4 months] in the ECOG PS 0–1 group vs. 9.3 months [95% CI, 4.9–12.8 months]; p = .2718) in the ECOG PS 2‐3 group. Conclusions The study results demonstrated no significant difference in PFS or OS among the ECOG PS 2–3 and ECOG PS 0–1 groups. Therefore, chemoimmunotherapy should be considered for patients who have ES‐SCLC with an ECOG PS of 2–3.
Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade
Champagne, Pierre‐Olivier , Chan, Erik, Ciporen, Jeremy , Chaskes, Mark B., Fernandez‐Miranda, Juan C. , Gardner, Paul A. , Hwang, Peter H. , Ji, Keven Seung Yong , Kalyvas, Aristotelis , Kong, Keonho A., McMillan, Ryan A. , O’Byrne, Jamie, Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Young, Sarah C. , Zenonos, Georgios A. , Zwagerman, Nathan T. , McMillan, Ryan, O'Byrne, Jamie, Peris Celda, Maria, Pinheiro-Neto, Carlos, Patel, Zara , Hwang, Peter H , Choby, Garret , Geltzeiler, Mathew , Almeida, João Paulo , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Snyderman, Carl H , Gompel, Jamie J. Van , Wang, Eric W

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 3, 2023 | Volume: 149 | Issue: 9 | Pages: 837

10.1001/jamaoto.2023.1939 | PMID 37535372 Get It

ImportanceCurrent olfactory neuroblastoma (ONB) staging systems inadequately delineate locally advanced tumors, do not incorporate tumor grade, and poorly estimate survival and recurrence.ObjectiveThe primary aims of this study were to (1) examine the clinical covariates associated with survival and recurrence of ONB in a modern-era multicenter cohort and (2) incorporate Hyams tumor grade into existing staging systems to assess its ability to estimate survival and recurrence.Design, Setting, and ParticipantsThis retrospective, multicenter, case-control study included patients with ONB who underwent treatment between January 1, 2005, and December 31, 2021, at 9 North American academic medical centers.InterventionStandard-of-care ONB treatment.Main Outcome and MeasuresThe main outcomes were overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) as C statistics for model prediction.ResultsA total of 256 patients with ONB (mean [SD] age, 52.0 [15.6] years; 115 female [44.9%]; 141 male [55.1%]) were included. The 5-year rate for OS was 83.5% (95% CI, 78.3%-89.1%); for DFS, 70.8% (95% CI, 64.3%-78.0%); and for DSS, 94.1% (95% CI, 90.5%-97.8%). On multivariable analysis, age, American Joint Committee on Cancer (AJCC) stage, involvement of bilateral maxillary sinuses, and positive margins were associated with OS. Only AJCC stage was associated with DFS. Only N stage was associated with DSS. When assessing the ability of staging systems to estimate OS, the best-performing model was the novel modification of the Dulguerov system (C statistic, 0.66; 95% CI, 0.59-0.76), and the Kadish system performed most poorly (C statistic, 0.57; 95% CI, 0.50-0.63). Regarding estimation of DFS, the modified Kadish system performed most poorly (C statistic, 0.55; 95% CI, 0.51-0.66), while the novel modification of the AJCC system performed the best (C statistic, 0.70; 95% CI, 0.66-0.80). Regarding estimation of DSS, the modified Kadish system was the best-performing model (C statistic, 0.79; 95% CI, 0.70-0.94), and the unmodified Kadish performed the worst (C statistic, 0.56; 95% CI, 0.51-0.68). The ability for novel ONB staging systems to estimate disease progression across stages was also assessed. In the novel Kadish staging system, patients with stage VI disease were approximately 7 times as likely to experience disease progression as patients with stage I disease (hazard ratio [HR], 6.84; 95% CI, 1.60-29.20). Results were similar for the novel modified Kadish system (HR, 8.99; 95% CI, 1.62-49.85) and the novel Dulguerov system (HR, 6.86; 95% CI, 2.74-17.18).Conclusions and RelevanceThe study findings indicate that 5-year OS for ONB is favorable and that incorporation of Hyams grade into traditional ONB staging systems is associated with improved estimation of disease progression.